Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Bests Annual Novel Drug Approval Record With Four Oks In One Week

Executive Summary

The agency's Dec. 21 approval of Giapreza became novel drug No. 46 of 2017, topping the 2015 mark of 45.

Advertisement

Related Content

Keeping Track: A Glut Of Big Approvals While Lartruvo Makes Its Market Exit
Keeping Track: Thumbs Up For Abbvie and GSK; Thumbs Down For Insys
Aerie's Rhopressa Approved Early For Glaucoma, 2018 Launch Planned
Aerie's Netarsudil Headed For Broad Indication With Only Subpopulation Efficacy
Aerie's Netarsudil's Safety Questions May Determine Fate At Advisory Committee
FDA's Gottlieb Pushing 'Seamless' Clinical Trials For Faster Development
Keeping Track Of Novel Agents: US FDA Approves Nerlynx And Vosevi, Turns Down Evenity; Macrilen Returns
Merck & Co, Pfizer Ertugliflozin Combo Data Beef Up Profile
Phase III Data For La Jolla's Angiotensin II Drug Leave Questions About Clinical Benefit
Keeping Track: US FDA Approves Siliq, Accepts Mylan/Biocon Pegfilgrastim Biosimilar

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel